{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:11:44Z","timestamp":1788635504204,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Applied Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Classic Galactosemia is a rare, autosomal recessive disease in which galactose is not metabolized properly due to severe deficiency\/absence of the galactose-1-phosphate uridylyltransferase (GALT) enzyme, converting to an aberrant and toxic metabolite, galactitol. Newborn screening and timely galactose-restricted diet can resolve acute symptoms and decrease fatalities. However, despite this, significant chronic, progressive morbidities remain which have a real impact upon daily life. To better understand the burden of disease, 20 in-depth qualitative interviews were undertaken with adult patients (n\u2009=\u200912), and their caregivers (n\u2009=\u20098), enrolled in the ACTION-Galactosemia trial, part of a clinical program designed to investigate the safety and efficacy of AT-007\u00a0(govorestat) in reducing toxic galactitol and long-term clinical outcomes in Classic Galactosemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Interviews revealed the substantial burden of Classic Galactosemia on patients and families. Most adults were not able to live independently, and all required support with day-to-day activities. Short- and long-term memory difficulties and tremors were identified as the most frequently experienced and challenging symptoms. Other difficulties such as fine motor skills and slow\/slurred speech contribute to the significant impact on daily activities, affecting ability to communicate and interact with others. Symptoms were first noticed in early childhood and worsened with age. Classic Galactosemia impacted all areas of daily functioning and quality of life, leading to social isolation, anxiety, anger\/frustration and depression. This demonstrates the significant burden of disease and challenges associated with Classic Galactosemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The impact on both patients and caregivers underscores the severity of the unmet medical need and the importance of pharmacological intervention to halt or prevent disease progression. Any treatment that could reduce symptoms or slow functional decline would ease the burden of this condition on patients and caregivers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02287-9","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T21:06:33Z","timestamp":1648501593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Qualitative interviews with adults with Classic Galactosemia and their caregivers: disease burden and challenges with daily living"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-7013","authenticated-orcid":false,"given":"Jason A.","family":"Randall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Raither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Shendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Burbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"issue":"3","key":"2287_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10545-017-0029-3","volume":"40","author":"AI Coelho","year":"2017","unstructured":"Coelho AI, Rubio-Gozalbo ME, Vicente JB, Rivera I. Sweet and sour: an update on classic galactosemia. J Inherit Metab Dis. 2017;40(3):325\u201342.","journal-title":"J Inherit Metab Dis"},{"key":"2287_CR2","unstructured":"Galactosemia. National Organization for Rare Diseases; 2020."},{"key":"2287_CR3","first-page":"79","volume":"15","author":"BM Pyhtila","year":"2014","unstructured":"Pyhtila BM, Shaw KA, Neumann SE, Fridovich-Keil JL. Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead. JIMD Rep. 2014;15:79\u201393.","journal-title":"JIMD Rep"},{"issue":"6","key":"2287_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s10545-009-1253-2","volume":"32","author":"A Bosch","year":"2009","unstructured":"Bosch A, Maurice-Stam H, Wijburg F, Grootenhuis M. Remarkable differences: the course of life of young adults with galactosaemia and PKU. J Inherit Metab Disease. 2009;32(6):706\u201312.","journal-title":"J Inherit Metab Disease"},{"issue":"5","key":"2287_CR5","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1542\/peds.113.5.e423","volume":"113","author":"AM Bosch","year":"2004","unstructured":"Bosch AM, Grootenhuis MA, Bakker HD, Heijmans HS, Wijburg FA, Last BF. Living with classical galactosemia: health-related quality of life consequences. Pediatrics. 2004;113(5):e423\u20138.","journal-title":"Pediatrics"},{"issue":"2","key":"2287_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/jpm11020075","volume":"11","author":"B Delnoy","year":"2021","unstructured":"Delnoy B, Coelho AI, Rubio-Gozalbo ME. Current and future treatments for classic galactosemia. J Person Med. 2021;11(2):75.","journal-title":"J Person Med"},{"issue":"3","key":"2287_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/jimd.12202","volume":"43","author":"M Haskovic","year":"2020","unstructured":"Haskovic M, Coelho AI, Bierau J, Vanoevelen JM, Steinbusch LK, Zimmermann LJ, et al. Pathophysiology and targets for treatment in hereditary galactosemia: a systematic review of animal and cellular models. J Inherit Metab Dis. 2020;43(3):392\u2013408.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2287_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10545-011-9372-y","volume":"35","author":"SE Waisbren","year":"2012","unstructured":"Waisbren SE, Potter NL, Gordon CM, Green RC, Greenstein P, Gubbels CS, et al. The adult galactosemic phenotype. J Inherit Metab Dis. 2012;35(2):279\u201386.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2287_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1215-1","volume":"14","author":"ME Hermans","year":"2019","unstructured":"Hermans ME, Welsink-Karssies MM, Bosch AM, Oostrom KJ, Geurtsen GJ. Cognitive functioning in patients with classical galactosemia: a systematic review. Orphanet J Rare Dis. 2019;14(1):1\u201311.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2287_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"MM Welsink-Karssies","year":"2020","unstructured":"Welsink-Karssies MM, Oostrom KJ, Hermans ME, Hollak CE, Janssen MC, Langendonk JG, et al. Classical galactosemia: neuropsychological and psychosocial functioning beyond intellectual abilities. Orphanet J Rare Dis. 2020;15(1):1\u201313.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2287_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s10545-012-9469-y","volume":"35","author":"B Hoffmann","year":"2012","unstructured":"Hoffmann B, Dragano N, Schweitzer-Krantz S. Living situation, occupation and health-related quality of life in adult patients with classic galactosemia. J Inherit Metab Dis. 2012;35(6):1051\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"2287_CR12","unstructured":"Methods to Identify What Is Important to Patients: Guidance for Industry. Silver Spring, MD: US Food and Drug Administration; 2019."},{"key":"2287_CR13","unstructured":"FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient's Voice in Medical Product Development and Regulatory Decision Making. US Food and Drug Administration; 2020."},{"issue":"6","key":"2287_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10545-012-9477-y","volume":"35","author":"PP Jumbo-Lucioni","year":"2012","unstructured":"Jumbo-Lucioni PP, Garber K, Kiel J, Baric I, Berry GT, Bosch A, et al. Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes. J Inherit Metab Dis. 2012;35(6):1037\u201349.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2287_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jpeds.2008.11.052","volume":"154","author":"J Hughes","year":"2009","unstructured":"Hughes J, Ryan S, Lambert D, Geoghegan O, Clark A, Rogers Y, et al. Outcomes of siblings with classical galactosemia. J Pediatr. 2009;154(5):721\u20136.","journal-title":"J Pediatr"},{"issue":"4","key":"2287_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.32457\/ijmss.2014.042","volume":"1","author":"M Cant\u00edn","year":"2014","unstructured":"Cant\u00edn M. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Reviewing the latest version. Int J Med Surg Sci. 2014;1(4):339\u201346.","journal-title":"Int J Med Surg Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02287-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T21:11:17Z","timestamp":1648501877000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02287-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02287-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study documents for this study were approved by an independent review board (Advarra, Pro00036607) as part of the main clinical trial documents. The study was conducted in compliance with Good Clinical Practice guidelines, including the International Conference on Harmonization Guidelines, and was consistent with the most recent version of the Declaration of Helsinki. All applicable local laws and regulatory requirements were followed throughout the study. Informed consent was obtained from all participants prior to conducting interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Clinical Outcomes Solutions is a health research consultancy paid to conduct this research. Applied Therapeutics is a pharmaceutical company which funded this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}